Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1193909
Author(s) Heim, Markus H.
Author(s) at UniBasel Heim, Markus H.
Year 2009
Title Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43
Journal Molecular and cellular biology : MCB : a publication of the American Society for Microbiology
Volume 29
Number 17
Pages / Article-Number 4841-51
Abstract Recombinant alpha interferon (IFN-alpha) is used for the treatment of viral hepatitis and some forms of cancer. During these therapies IFN-alpha is injected once daily or every second day for several months. Recently, the long-acting pegylated IFN-alpha (pegIFN-alpha) has replaced standard IFN-alpha in therapies of chronic hepatitis C because it is more effective, supposedly by inducing a long-lasting activation of IFN signaling pathways. IFN signaling in cultured cells, however, becomes refractory within hours, and little is known about the pharmacodynamic effects of continuously high IFN-alpha serum concentrations. To investigate the behavior of the IFN system in vivo, we repeatedly injected mice with IFN-alpha and analyzed its effects in the liver. Within hours after the first injection, IFN-alpha signaling became refractory to further stimulation. The negative regulator SOCS1 was rapidly upregulated and likely responsible for early termination of IFN-alpha signaling. For long-lasting refractoriness, neither SOCS1 nor SOCS3 were instrumental. Instead, we identified the inhibitor USP18/UBP43 as the key mediator. Our results indicate that the current therapeutic practice using long-lasting pegIFN-alpha is not well adapted to the intrinsic properties of the IFN system. Targeting USP18 expression may allow to exploit the full therapeutic potential of recombinant IFN-alpha.
Publisher American Society for Microbiology
ISSN/ISBN 1098-5549
edoc-URL http://edoc.unibas.ch/dok/A6004147
Full Text on edoc No
Digital Object Identifier DOI 10.1128/MCB.00224-09
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/19564419
ISI-Number WOS:000268813100021
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.406 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
26/04/2024